Clinical trials in Genk – page 21

1 420 clinical trials in Genk, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Genk at a glance

1 420

clinical trials

Research sites1

Quick filters

1 420 trials in Genk

Open in trial search

Adenovirus infection

Recruiting

Comparing brincidofovir and cidofovir for treating adenovirus infection in children and adults after stem cell transplantation

InvestigationalNo placebo

Comparing brincidofovir and cidofovir for treating adenovirus infection in children and adults after stem cell transplantation

InvestigationalNo placebo

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Brincidofovir
Sponsor:Symbio Pharmaceuticals Ltd.

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Alteplase
Sponsor:Insel Gruppe AG

Contact Research Centre

Colitis ulcerative

Recruiting

Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

Investigational

Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

Investigational

Belgium

Participants:0–17 years
Substances:Risankizumab
Sponsor:Abbvie Deutschland GmbH & Co. KG

Contact Research Centre

Dry age-related macular degeneration

Recruiting

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Xelafaslatide
Sponsor:ONL Therapeutics Inc.

Contact Research Centre

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Novartis Pharma AG

Contact Research Centre

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Belgium

Participants:0–17 years
Substances:Vedolizumab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Cholangiocarcinoma

Recruiting

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ivosidenib
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Nucresiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Genk

What the registry says about research in the country

01 Respiratory Disease Trials

Extensive research focusing on respiratory syncytial virus (RSV) and influenza prevention in older adults. Studies evaluate innovative vaccine combinations and immune responses in participants over 60 years.

RSV and human metapneumovirus vaccines
High-dose Influenza vaccines
Vaccine co-administration studies

Multiple trials aim to enhance protection against respiratory infections in vulnerable populations.

02 Cardiovascular Research

Comprehensive studies addressing various aspects of heart disease and related conditions, including innovative treatments for hypertrophic cardiomyopathy and heart failure.

Acute Heart Failure treatments
Pulmonary Hypertension therapies
Cardiovascular disease prevention

Trials explore new therapeutic approaches for managing complex cardiac conditions.

03 Autoimmune Conditions

Clinical research examining treatments for various autoimmune disorders, including innovative therapies for rheumatoid arthritis and Sjögren's syndrome.

Psoriatic Arthritis treatments
Rheumatoid Arthritis therapies
Primary Sjögren's Disease interventions

Studies focus on improving treatment outcomes and quality of life for patients with autoimmune conditions.

Back to Belgium All countries